JP2022546806A5 - - Google Patents

Info

Publication number
JP2022546806A5
JP2022546806A5 JP2022513248A JP2022513248A JP2022546806A5 JP 2022546806 A5 JP2022546806 A5 JP 2022546806A5 JP 2022513248 A JP2022513248 A JP 2022513248A JP 2022513248 A JP2022513248 A JP 2022513248A JP 2022546806 A5 JP2022546806 A5 JP 2022546806A5
Authority
JP
Japan
Prior art keywords
aliphatic
group
tumor
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546806A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050932 external-priority patent/WO2021042171A1/en
Publication of JP2022546806A publication Critical patent/JP2022546806A/ja
Publication of JP2022546806A5 publication Critical patent/JP2022546806A5/ja
Priority to JP2025115718A priority Critical patent/JP2025148436A/ja
Pending legal-status Critical Current

Links

JP2022513248A 2019-09-04 2020-09-04 癌免疫療法 Pending JP2022546806A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025115718A JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019903262A AU2019903262A0 (en) 2019-09-04 Cancer immunotherapy
AU2019903262 2019-09-04
AU2019904864A AU2019904864A0 (en) 2019-12-20 Cancer immunotherapy (2)
AU2019904864 2019-12-20
PCT/AU2020/050932 WO2021042171A1 (en) 2019-09-04 2020-09-04 Cancer immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025115718A Division JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Publications (2)

Publication Number Publication Date
JP2022546806A JP2022546806A (ja) 2022-11-09
JP2022546806A5 true JP2022546806A5 (cg-RX-API-DMAC7.html) 2023-09-12

Family

ID=74851930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513248A Pending JP2022546806A (ja) 2019-09-04 2020-09-04 癌免疫療法
JP2025115718A Pending JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025115718A Pending JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Country Status (6)

Country Link
US (1) US20230043518A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025204A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022546806A (cg-RX-API-DMAC7.html)
CN (2) CN114364378A (cg-RX-API-DMAC7.html)
AU (1) AU2020340468B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021042171A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
WO2021042174A1 (en) * 2019-09-04 2021-03-11 Ena Therapeutics Pty Ltd Cancer treatment
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100965A1 (ja) * 2003-05-15 2004-11-25 Japan Science And Technology Agency 免疫刺激剤
GB0907989D0 (en) * 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
CA2811957C (en) * 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IN2014CN02581A (cg-RX-API-DMAC7.html) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3429618B1 (en) * 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
AU2018241248B2 (en) * 2017-03-31 2025-01-23 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist
IL275360B2 (en) * 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds

Similar Documents

Publication Publication Date Title
US10722591B2 (en) Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
JP2021521111A5 (cg-RX-API-DMAC7.html)
JP2025160318A5 (cg-RX-API-DMAC7.html)
IL269830B2 (en) Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
JP2025160317A5 (cg-RX-API-DMAC7.html)
JP2022542222A5 (cg-RX-API-DMAC7.html)
JP2019043957A5 (cg-RX-API-DMAC7.html)
JP2020075934A5 (cg-RX-API-DMAC7.html)
JP2024542260A5 (cg-RX-API-DMAC7.html)
JP2016505586A5 (cg-RX-API-DMAC7.html)
JP2016510030A5 (cg-RX-API-DMAC7.html)
JP2022546807A5 (cg-RX-API-DMAC7.html)
JP2016521257A5 (cg-RX-API-DMAC7.html)
RU2017145921A (ru) Пептидомиметические макроциклы
JP2013511540A5 (cg-RX-API-DMAC7.html)
JP2013500304A5 (cg-RX-API-DMAC7.html)
JP2016510030A (ja) 薬物組み合わせ
JP2022539091A5 (cg-RX-API-DMAC7.html)
JP2022546806A (ja) 癌免疫療法
JP2021513990A5 (cg-RX-API-DMAC7.html)
WO2022177993A1 (en) Self-assembling nanoparticles based on amphiphilic peptides
JP2024523411A5 (cg-RX-API-DMAC7.html)
AU2019321091C1 (en) Conjugates for use in methods of treating cancer
WO2020118096A1 (en) Anti-cancer activity of adamantane derivatives
JP2023552490A5 (cg-RX-API-DMAC7.html)